| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |